Wedbush raised the firm’s price target on Larimar Therapeutics (LRMR) to $13 from $12 and keeps an Outperform rating on the shares. Overall, the Q4 update was as anticipated as Larimar prepares for its nomlabofusp regulatory submission in June 2026, the firm says. Management reiterated its cash runway extends into Q2 2027, following the recent financing. More near term, Wedbush is focused on the updated open-label data release in Q2.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- Larimar Therapeutics: Undervalued First-in-Class Frataxin Replacement with Favorable Regulatory Path and 2026 Inflection Point
- Larimar Therapeutics reports Q4 EPS (73c), consensus (55c)
- LRMR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Larimar Advances Nomlabofusp Toward 2026 BLA Submission
- Larimar Therapeutics price target raised to $12 from $11 at Wedbush